PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
PALVELLA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$122.96+2.66 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $1.77B
- P/E (TTM)
- –
- Dividend yield
- –
Palvella Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.77B | $166.30M |
| Enterprise Value | $1.52B | $88.19M |
| PB Ratio | 8.17 | 2.03 |
| P/TBV Ratio | 8.17 | 2.29 |
Income (trailing twelve months)
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$57.74M | -$21.40M |
| Pretax Income | -$61.70M | -$14.34M |
| Net Income | -$61.70M | -$22.46M |
| EBITDA | -$57.74M | -$16.91M |
| EPS (Diluted) | -$4.82 | -$0.83 |
Returns
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -46.6% | -53.2% |
| Return on Assets (ROA) | -37.7% | -40.9% |
| Return on Capital Employed (ROCE) | -23.9% | -38.1% |
Balance sheet
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $250.60M | $61.43M |
| Net Cash (Debt) | $250.60M | $15.35M |
| Net Cash Per Share | $17.39 | $0.66 |
| Equity (Book Value) | $216.87M | $49.09M |
| Book Value Per Share | $15.05 | $1.37 |
| Tangible Book Value | $216.87M | $23.52M |
| Working Capital | $241.08M | $76.81M |
Financial position
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 21.18 | 3.34 |
| Quick Ratio | 20.98 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$36.51M | -$12.35M |
Efficiency
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$2.13M | -$703.34K |
| Employee Count | 29 | 74 |
Dividends and yields
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -3.48% | -23.3% |
Shares
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 14,408,400 | 58,127,000 |
| Shares Change (YoY) | 83.7% | 10.9% |
| Shares Change (QoQ) | 0.57% | 0.54% |
| Float | 12,417,600 | 49,136,700 |
| Shares Held by Insiders | 13.8% | 11.6% |
| Shares Held by Institutions | 97.8% | 59.4% |
Taxes
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Income Tax | $0 | $79.87K |
Scores
| Measure | Palvella Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 28.44 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Palvella Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.